Antibiotics (Oct 2022)

Discovery and Preliminary Structure-Activity Investigation of 3-Substituted-1<i>H</i>-imidazol-5-yl-1<i>H</i>-indoles with In Vitro Activity towards Methicillin-Resistant <i>Staphylococcus aureus</i>

  • Steven A. Li,
  • Rebecca J. Zheng,
  • Kenneth Sue,
  • Marie-Lise Bourguet-Kondracki,
  • Azza Troudi,
  • Jean Michel Brunel,
  • Brent R. Copp,
  • Melissa M. Cadelis

DOI
https://doi.org/10.3390/antibiotics11101450
Journal volume & issue
Vol. 11, no. 10
p. 1450

Abstract

Read online

Antibiotics have been the cornerstone of modern medicine saving lives by virtue of being able to cure infectious diseases and to prevent infections in those who are immune compromised. Their intense use has led to a surging increase in the incidence of antibiotic-resistant bacteria resulting in a desperate need for antibiotics with new mechanisms of action. As part of our search for new antimicrobials we have screened an in-house library of compounds and identified two 3-substituted-1H-imidazol-5-yl-1H-indoles as weak growth inhibitors (MIC 16 µg/mL) against methicillin-resistant Staphylococcus aureus (MRSA). An extensive library of analogues was prepared using the Van Leusen three-component reaction, biological evaluation of which led to the identification of two analogues (26 and 32) with favorable anti-MRSA activity (MIC ≤ 0.25 µg/mL) which also lacked cytotoxic or hemolytic properties. The screening campaign also identified two derivatives, a phenethyl-indole-imidazole 57 and a 5-phenyl-1H-imidazole 111 that were non-toxic selective antifungals towards Cryptococcus neoformans. These results have identified 3-substituted-1H-imidazol-5-yl-1H-indoles and 5-phenyl-1H-imidazoles as new structural scaffolds for further investigation as anti-MRSA and anti-C. neoformans agents, respectively.

Keywords